ClinicalTrials.gg
CompletedNCT00711958Updated Sep 5, 2017Results posted

Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients

A Phase 3 interventional study of HX575, solution for injection (s.c.) and ERYPO®, Janssen-Cilag, solution for injection (s.c.) in Anemia, sponsored by Sandoz. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-05.

Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing Epoetin Alfa in Anemia — 2 open to participants now, 3 under way, 2 of them phase 3. Epoetin Alfa · Anemia.

Enrollment
44th of 112
114 · median 71
Started
2004
with 13 others
Phase 3
45 of 126
1 open now
Registered
102nd of 126
by date
Lead sponsor
3 of 126
Sandoz

Among the 126 studies testing Epoetin Alfa in Anemia, this one is the 44th largest by enrollment of the 112 interventional ones that give a count, is one of 14 that started in 2004, is one of 45 in phase 3, and was the 102nd registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 126 studies testing Epoetin Alfa in Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing Epoetin Alfa in Anemia, or all of them as a file.
02

Study summary

This is a randomized, double-blind, multicenter clinical phase III study involving about 105 cancer patients aged >18 years who are receiving palliative chemotherapy and who are suffering from chemotherapy associated anemia. A standard treatment group (ERYPO®) will be included to provide a reference reflecting current standard medical practice.

Read the detailed description

Eligible patients were randomized to one of two different treatment groups (EPO HEXAL or ERYPO) in a 2:1 ratio. Patients received double-blind treatment for a period of 12 weeks. Following randomization the patients were treated subcutaneously with a dose of 150 IU/kg body weight of study drug three times per week. Dose adjustments to 300 IU/kg body weight three times per week were to be done if hemoglobin (Hb) increased \<1.0 g/dL or the reticulocyte count increased \<40,000 /μl after 4 weeks or if Hb increased \<2.0 g/dL after 8 weeks of treatment. The primary endpoint was the Hb response in the EPO HEXAL group during weeks 5-12 of the study defined as absolute increase in Hb value of 2.0 g/dL from the mean value of the screening/baseline period in the absence of red blood cell transfusion during the preceding 4 weeks. For that purpose, Hb levels were measured at the weekly study visits by a central laboratory. Further parameters of treatment efficacy, safety and tolerability were recorded.

03

Conditions studied

  • Anemia

Browse trials for

Keywords

  • Chemotherapy associated anemia in cancer patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a confirmed diagnosis of solid tumors
  • Patients who receive cyclic palliative chemotherapy with a cycle duration of 1 -4 weeks (for at least 12 weeks) during the study
  • Patients with chemotherapy associated anemia ( \< 10.0 g/dl at screening)
  • of at least 6 months Age: > 18
  • performance status of 0, 1 or 2
  • Serum ferritin greater or equal to 100 µg/l and/or saturated transferrin levels greater or equal to 20 %
  • Adequate renal function (serum creatinine below or equal to 2.0 mg/dl)
  • Adequate hepatic function ( \< 1.5 times
  • Patients with ability to follow study instructions, likely to complete all required visits and able to perform the quality of life assessment
  • Written of the patient

Exclusion criteria

Exclusion Criteria:

  • Patients who receive curative intended chemotherapy
  • Known primary or of the central nervous system
  • Known primary or metastatic malignancy of bone marrow
  • Primary hematologic disorder (e.g. myelodysplastic syndrome, sickle cell anemia, hematological malignancy, acute leukemia)
  • Thrombotic events during the last 6 months
  • Suspicion or known PRCA (pure red cell aplasia)
  • Transfusion of white blood cells or packed red blood cells (more than 2 packs) within 4 weeks and any transfusion of white blood cells or packed red blood cells within 2 weeks prior to randomization (visit 0)
  • Anemia due to overt bleeding or hemolysis within 2 weeks before screening
  • Erythropoietin or Darbepoietin therapy within 8 weeks before screening, including any form of erythropoietin (e.g. gene-activated erythropoietin, novel erythropoiesis stimulating protein)
  • Radiation therapy during the study, radiation therapy induced anemia
  • Therapy with cyclosporine
  • Chemotherapy which causes predictable treatment with peripheral-blood progenitor therapy, e.g. G-CSF
  • Clinical evidence of current uncontrolled hyperparathyroidism (serum parathyroid hormone >1500 pg/mL)
  • Major surgery within 14 days prior to randomization
  • Treatment with antiepileptics within the last 5 years
  • Previously diagnosed or acute hepatitis infection
  • Uncontrolled hypertension, defined as a diastolic blood pressure measurement >110mm Hg during the screening period
  • History of congestive heart failure ( class III, IV)
  • Unstable angina pectoris, active cardiac disease, cardiac infarction during the last six months before screening
  • Evidence of acute infectious disease or serious active inflammatory disease within four weeks before screening (Visit -1) or during the screening/baseline period
  • Known allergy to one of the ingredients of the test or reference products or to mammalian-derived products
  • Pregnancy, breastfeeding women or women not using adequate measures
  • Patients who participate simultaneously in another clinical study or who have participated in a study in the month preceding the start of this study or previously randomized to this study (except studies with approved medications in an approved indication, with an approved dosing regimen including approved treatment combinations)
  • Suspicion of any non-compliance
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    HX575 epoetin alfa Hexal AG

    HX575 (erythropoietin alfa of the Sponsor Hexal AG). Eligible patients to be randomized in ratio 2:1 and to be subcutaneously treated (solution for injection (s.c.)) for 12 weeks with HX575 in pre-filled syringes. The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range. Application of the drug required at least once per week and allowed maximum three times per week.

    Drug: HX575, solution for injection (s.c.)

  • Active comparator
    ERYPO® Janssen-Cilag

    ERYPO® Janssen-Cilag, Germany. Eligible patients were treated subcutaneously (solution for injection (s.c.)) with ERYPO® (Janssen-Cilag, Germany) in pre-filled syringes for 12 weeks.The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range. Application of the drug required at least once per week and allowed maximum three times per week.

    Drug: ERYPO®, Janssen-Cilag, solution for injection (s.c.)

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy of HX575 in the Treatment of Chemotherapy Associated Anemia

    Proportion of patients with a change in hemoglobin levels more than 2 g/dL under treatment with HX575, estimated between weeks 5-12.

    Time frame: 5-12 weeks

07

Results

Posted Aug 2, 2017

Participant flow

23 cancer centers, in Germany and Romania .

Participant flow — Overall Study
MilestoneHX575 Epoetin Alfa Hexal AGERYPO® Janssen-Cilag
Started7440
Completed4117
Not completed3323
Withdrew: Withdrawal by subject68
Withdrew: Lack of efficacy31
Withdrew: Clinical deterioration10
Withdrew: Adverse event97
Withdrew: Protocol violation10
Withdrew: Lost to follow-up22
Withdrew: Death105
Withdrew: Progression of disease10

Outcome measures

PrimaryEfficacy of HX575 in the Treatment of Chemotherapy Associated Anemia

Proportion of patients with a change in hemoglobin levels more than 2 g/dL under treatment with HX575, estimated between weeks 5-12.

Time frame:
5-12 weeks
Reported as:
Count of participants · Participants
Efficacy of HX575 in the Treatment of Chemotherapy Associated Anemia
ParticipantsHX575 Epoetin Alfa Hexal AGERYPO® Janssen-Cilag
Efficacy of HX575 in the Treatment of Chemotherapy Associated Anemia3715

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HX575 Epoetin Alfa Hexal AG18/74 (24.3%)34/74 (45.9%)62/74 (83.8%)
ERYPO® Janssen-Cilag12/40 (30%)18/40 (45%)30/40 (75%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventHX575 Epoetin Alfa Hexal AGERYPO® Janssen-Cilag
Neoplasms malignant site unspecified NECNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/746/40
Renal failure and impairmentRenal and urinary disorders2/745/40
Asthenic conditionsGeneral disorders4/740/40
Metastases to specified sitesNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/742/40
Peritoneal and retroperitoneal disordersGastrointestinal disorders1/742/40
Febrile disordersGeneral disorders0/742/40
Urinary abnormalitiesRenal and urinary disorders1/742/40
Renal obstructive disordersRenal and urinary disorders0/742/40
Ventricular arrhythmias and cardiac arrestCardiac disorders2/742/40
Ischaemic coronary artery disordersCardiac disorders0/742/40
Most frequent other events
Showing 10 of 15
Most frequent other events
EventHX575 Epoetin Alfa Hexal AGERYPO® Janssen-Cilag
NauseaGastrointestinal disorders17/7414/40
VomitingGastrointestinal disorders13/749/40
AstheniaGeneral disorders15/746/40
AnorexiaMetabolism and nutrition disorders12/747/40
ConstipationGastrointestinal disorders9/746/40
FatigueGeneral disorders5/746/40
Abdominal painGastrointestinal disorders9/745/40
PyrexiaGeneral disorders9/744/40
DiarrhoeaGastrointestinal disorders4/744/40
Oedema peripheralGeneral disorders5/744/40

Baseline characteristics

50 patients found to have a major protocol violation , excluded from the ITT population only (31 and 19 in EPO HEXAL and ERYPO groups), none from the Safety Analysis population. Major deviations: early patient withdrawal (consent or due to AE), and lack of endpoint value in observation period (no Hemoglobin value over weeks 5 to 12)

Age, Customized
Age, Customized(Participants)HX575 Epoetin Alfa Hexal AGERYPO® Janssen-CilagTotal
18-39 years336
40-64 years431861
≥65 years281947
Sex: Female, Male
Sex: Female, Male(Participants)HX575 Epoetin Alfa Hexal AGERYPO® Janssen-CilagTotal
Female411758
Male332356
Region of Enrollment
Region of Enrollment(Participants)HX575 Epoetin Alfa Hexal AGERYPO® Janssen-CilagTotal
Romania361854
Germany382260
most frequent site of primary malignancy
most frequent site of primary malignancy(Participants)HX575 Epoetin Alfa Hexal AGERYPO® Janssen-CilagTotal
ovary17724
lung13619
pancreas549
stomach448
breast8311
other271643
08

Study locations

19 sites
  • Gemeinschaftspraxis Drs. Brudler, Heinrich, Bangerter
    Augsburg, 86150, Germany
  • Gemeinschaftspraxis mit Schwerpunkt Hämatologie und Internistische Onkologie
    Bad Soden, 65812, Germany
  • Poliklinik am Paritätischen Krankenhaus
    Berlin, 10365, Germany
  • Schwerpunktpraxis für Brustkrankheiten und Gynäkologische Onkologie
    Berlin, 10367, Germany
  • Oskar-Helene-Heim
    Berlin, 14195, Germany
  • Praxis Drs. Marschner, Zeiss, Kirste
    Freiburg, 79106, Germany
  • DRK-Krankenhaus
    Luckenwalde, 14943, Germany
  • Praxis für Onkologie
    Munich, 80637, Germany
  • Praxis Drs. Kowolik/Prechtl
    Munich, 81925, Germany
  • Klinikum Nürnberg, 5. Medizinische Klinik Haus 12, Zimmer Nr. 13
    Nürnberg, 90419, Germany
  • Gemeinschaftspraxis
    Stuttgart, 70173, Germany
  • Robert-Bosch-Krankenhaus
    Stuttgart, 70376, Germany
  • Universitätsklinikum Tübingen Medizinische Klinik 1
    Tübingen, 72076, Germany
  • Gemeinschaftspraxis für internistische Onkologie
    Velbert, 42551, Germany
  • Praxis für internistische Onkologie
    Weiden, 92637, Germany
  • Oncologic Institute
    Cluj-Napoca, 400015, Romania
  • Country hospital Oradea
    Oradea, 410032, Romania
  • County Hospital Satu-Mare
    Satu-Mare, 440192, Romania
  • Oncomed SRL Timisoara
    Timisoara, 300239, Romania
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004, a primary completion of Jul 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 12 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2008
First posted
Jul 9, 2008
Start
Nov 2004
Primary completionActual
Jul 2005
CompletionActual
Dec 2005
Results first posted
Aug 2, 2017
Last update
Sep 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00711958
Lead sponsor
Sandoz
Collaborators
Hexal AG
Responsible party
Sponsor
First posted
Jul 9, 2008
Start date
Nov 2004
Primary completion
Jul 2005
Completion
Dec 2005
Results posted
Aug 2, 2017
Last update
Sep 5, 2017

Study contacts

Andrea Vetter, Dr.
study chair · Hexal AG

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion